Carcinogenicity Evaluation: ComparisoN of Tumor Data from Dual Control Groups in the Sprague–Dawley Rat

Toxicologic Pathology

Volumn 33, Issue 2, 2005, Pages 283-291

  Baldrick, Paul ^a  

^a UK   (United Kingdom)

Author keywords

benign and malignant neoplasms; carcinogenicity; dual control groups; genetic drift; Sprague Dawley rat; survival

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARCINOGENICITY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; GENETIC DRIFT; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RISK ASSESSMENT;

ANIMALS; CARCINOGENICITY TESTS; CONTROL GROUPS; FEMALE; GREAT BRITAIN; INCIDENCE; MALE; NEOPLASMS; RATS; REFERENCE VALUES;

ANIMALIA; RODENTIA;

EID: 15044344653     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/019262390908371     Document Type: Article

References (29)

1. Attia MA Neoplastic and non-neoplastic lesions in the mammary gland, endocrine and genital organs in aging male and female Sprague–Dawley rats Arch Toxicol 1996 70 461 473
2. Britton LD, Downs N, Mullins P, Mitchell D The most appropriate strain for rat carcinogenicity bioassays? Toxicol Sci 2004 78 1–S 560
3. CDER Guidance for industry: statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals Issued as draft document in May 2001 2001 Available at: 〈http:\\www.fda.gov\cder\guidance〉
4. Chandra M, Riley MGI, Johnson DE Spontaneous neoplasms in aged Sprague–Dawley rats Arch Toxicol 1992 66 496 502
5. Contrera JF, Jacobs AC, DeGeorge JJ Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals Reg Toxicol Pharm 1997 25 2 130-45
6. Fairweather WR, Bhattacharyya A, Ceuppens PP, Heimann G, Hothorn LA, Kodell RL, Lin KK, Mager H, Middleton BJ, Slob W, Soper KA, Stallard N, Ventre J, Wright J Biostatistical methodology in carcinogenicity studies Drug Inform Jour 1998 32 401 421
7. FDA Red Book Toxicological principles for the safety assessment of direct food additives and color additives used in food 1982 U.S. Food and Drug Administration, Bureau of Foods
8. Gopinath C Spontaneous tumor rates: their use to support rodent bioassays Toxicol Pathol 1994 22 2 160-4
9. Greim H, Gelbke HP, Reuter U, Thielmann HW, Edler L Evaluation of historical controls in carcinogenicity studies Hum Exp Toxicol 2003 22 541-9
10. Guidelines Volume 3B Medicinal products for human use. Safety, environment and information The Rules Governing Medicinal Products in the European Union 1998 Luxembourg Office for Official Publications of the European Communities
11. Hardisty JF Factors influencing laboratory animal spontaneous tumor profiles Toxicol Pathol 1985 13 2 95 104
12. 1 mice in two-year carcinogenicity studies: a National Toxicology Program update Toxicol Pathol 1998 26 3 428-41
13. Haseman JK, Huff J, Boorman GA Use of historical control data in carcinogenicity studies in rodents Toxicol Pathol 1984 12 2 126-35
14. Haseman JK, Ney E, Nyska A, Rao GN Effect of diet and animal care/housing protocols on body weight, survival, tumor incidences, and nephropathy severity of F344 rats in chronic studies Toxicol Pathol 2003 31 674-81
15. Haseman JK, Winbush JS, O'Donnell MW Jr Use of dual control groups to estimate false positive rates in laboratory animal carcinogenicity studies Fund App Toxicol 1986 7 4 573-84
16. Hooks WN, Harling RJ A review of the choice of rat strains in tumorigenicity studies Toxicol Sci 2001 60 1 260
17. ICH S1C Dose selection for carcinogenicity studies of pharmaceuticals Operational March 1995 1995 Available at: 〈http:\\www.eudra.org\humandocs〉
18. ICH S1A Guideline on the need for carcinogenicity studies of pharmaceuticals Operational July 1996 1996 Available at: 〈http:\\www.eudra.org\humandocs〉
19. ICH S1C(R) Guidance on dose selection for carcinogenicity studies of pharmaceuticals: addendum on a limit dose and related notes Operational December 1997 1997 Available at: 〈http:\\www.eudra.org\humandocs〉
20. ICH S1B Testing for carcinogenicity of pharmaceuticals Operational February 1998 1998 Available at: 〈http:\\www.eudra.org\humandocs〉
21. Japan's and ICH Guidelines for New Drug Registration 1999 Yakuji Nippon Ltd
22. Kaspareit J, Rittinghausen S Spontaneous neoplastic lesions in Harlan Sprague–Dawley rats Exp Toxicol Pathol 1999 51 105-7
23. Keenan KP, Soper KA, Smith PF, Ballam GD, Clark RL Diet, overfeeding and moderate dietary restriction in control Sprague–Dawley rats: 1. Effects on spontaneous neoplasms Toxicol Pathol 1995 23 3 269-86
24. Knight EV, Bryant S, Kimball B, Eitzen BH, Legrand EK, Barrett DS Two-year evaluation of clinical and gross pathological parameters in Sprague–Dawley rats from different suppliers Toxicol Pathol 1996 24 788-9
25. McMartin DN, Sahota PS, Gunson DE, Hsu HH, Spaet RH Neoplasms and related proliferative lesions in control Sprague–Dawley rats from carcinogenicity studies. Historical data and diagnostic considerations Toxicol Pathol 1992 20 2 212-25
26. OECD 451 Carcinogenicity Studies, adopted May 1981 OECD guidelines for the testing of chemicals 1993 2 Paris Organisation for economic cooperation and development
27. Perry R, Menton R Statistical methods in 2-year rodent carcinogenicity studies Toxicol Sci 2004 32 Suppl 1 157
28. Son WC, Gopinath C Early occurrence of spontaneous tumors in CD-1 mice and Sprague–Dawley rats Toxicol Pathol 2004 32 4 371-4
29. Tennekes H, Gembardt C, Dammann M, van Ravenwaay B The stability of historical control data for common neoplasms in laboratory rats: adrenal gland (medulla), mammary gland, liver, endocrine pancreas and pituitary gland Reg Toxicol Pharm 2004 40 18 27